CN1823811A - Application of physalis alkekengi polysaccharide in preparation of medicine and health care product for treating diabetes - Google Patents
Application of physalis alkekengi polysaccharide in preparation of medicine and health care product for treating diabetes Download PDFInfo
- Publication number
- CN1823811A CN1823811A CNA2005101191454A CN200510119145A CN1823811A CN 1823811 A CN1823811 A CN 1823811A CN A2005101191454 A CNA2005101191454 A CN A2005101191454A CN 200510119145 A CN200510119145 A CN 200510119145A CN 1823811 A CN1823811 A CN 1823811A
- Authority
- CN
- China
- Prior art keywords
- medicine
- polysaccharide
- application
- product
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An application of the Calyx Seu Fructus Physalis' polyose in preparing the medicine and hypoglycemic health-care food for treating diabetes is disclosed. Its preparing process includes such steps as adding the fruits of Calyx Seu Fructus Physalis in deionized water, heating, filtering, concentrating, stirring, depositing, centrifugal separation and vacuum drying.
Description
Technical field
The invention belongs to the application in the pharmaceutical field, be specifically related to the application of Calyx Seu Fructus Physalis fruit polysaccharide in preparation treatment diabetes medicament and health-caring product capable of reducing blood sugar.
Background technology
Along with social progress and rapid economic development, the sickness rate of diabetes increases day by day, and young and middle-aged people doubles " main forces " of old people's speed adding diabetes.Therefore, become the focus and the development trend of the world, domestic research with preventing the medicine relevant with the treatment diabetes.
At present, the blood sugar lowering market of China accounts for 73.68% of whole market share based on Western medicine; Chinese patent medicine is auxilliary, accounts for 24.7%.What account for blood sugar lowering series products absolute advantages share mainly is the chemical classes prescription drugs, though effect is more obvious, side effect such as the drug resistance that causes of taking medicine for a long time, Drug resistance, lesions of liver and kidney make diabetics feel more painful.And plant component, commonly used Chinese medicine ingredients such as vegetable polysaccharides and saponin etc. of the traditional Chinese medical science particularly, not only toxic and side effects is little, and much medicine has blood fat reducing simultaneously, improves multiple effects such as immunity, endocrine regulation, and diabetic complication is had prevention and therapeutical effect.Thereby from medicinal plants, excavate the diabetes natural drug of better efficacy and health product have great importance and vast market prospect.
Summary of the invention
The purpose of this invention is to provide a kind of from the Calyx Seu Fructus Physalis fruit, extract remarkable blood sugar decreasing effect and polysaccharide medicine that has no side effect or health product are arranged.
Concrete extraction step of the present invention:
Step 1: fresh or exsiccant Calyx Seu Fructus Physalis really adds doubly (V/V) deionized water ebuillition of heated 2-3 hour of 5-10, filtration residue; Reuse 5-10 is (V/V) deionized water extraction twice doubly, merging filtrate; Filtrate is concentrated into about 1/15 of original volume, adds 4-5 times of ethanol and stir precipitation, precipitate is through centrifugal, and vacuum drying obtains the semifinished product of total polysaccharides.
Step 2: crude polysaccharides is dissolved in the deionized water, and it is centrifugal to freeze molten back repeatedly, abandons precipitation; Polysaccharide in the supernatant is mixed with 2% aqueous solution, and to make its final concentration be 30% and adjust pH to 2.5 to add ethanol, and static spending the night abandoned precipitation after centrifugal; Making its final concentration to the continuous adding of supernatant relaying alcoholic solution is 70%, static spending the night, and precipitate is through centrifugal, and vacuum drying, the crude polysaccharides A that obtains can be used as diabetics or the hyperglycemia sub-health population is alleviated and the health product of prevent diabetes.
Step 3: the crude polysaccharides A that step 2 is obtained passes through Sephadex G-200 column chromatography, and eluent is 0.15M NaCl, and eluent detects through the sulphuric acid phynol method, gets male portion and divides merging, and lyophilization gets sample B.This sample detects through HPLC, and the result is single symmetrical peak, proves that this polysaccharide is pure product, and these pure product can be used as the treatment medicine of diabetics.
Advantage of the present invention:
1. to have illustrated Calyx Seu Fructus Physalis fruit polysaccharide particularly be hypoglycemic effective medicinal ingredient in the present invention, is natural drug or the health product with remarkable hypoglycemic activity.The Calyx Seu Fructus Physalis fruit polysaccharide of purification can be used for treating diabetes medicament, and its semifinished product can be used for diabetics or the hyperglycemia sub-health population is alleviated and the health product of prevent diabetes.And other correlational studyes and invention are extremely coarse extract, and active ingredient is indeterminate, and value is low.
2. extraction process is easy, and is with low cost.
3. material source is extensive.The Calyx Seu Fructus Physalis adaptability is very strong, very easily extensive artificial plantation, in case plantation can be survived for many years, the plantation Calyx Seu Fructus Physalis of scale can make plantation peasant household shake off poverty and set out on the road to prosperity.
The specific embodiment:
Step 1: fresh or exsiccant Calyx Seu Fructus Physalis fruit 1Kg adds doubly (V/V) deionized water ebuillition of heated 2-3 hour of 5-10, filtration residue; Reuse 5-10 is (V/V) deionized water extraction twice doubly, merging filtrate; Filtrate is concentrated into about 1/15 of original volume, adds 4-5 times of ethanol and stir precipitation, precipitate is through centrifugal, and vacuum drying obtains the semifinished product 32g of total polysaccharides.
Step 2: crude polysaccharides is dissolved in the deionized water, and it is centrifugal to freeze molten back repeatedly, abandons precipitation; Polysaccharide in the supernatant is mixed with 2% aqueous solution, and to make its final concentration be 30% and adjust pH to 2.5 to add ethanol, and static spending the night abandoned precipitation after centrifugal; Making its final concentration to the continuous adding of supernatant relaying alcoholic solution is 70%, static spending the night, and precipitate is through centrifugal, and vacuum drying, the crude polysaccharides A 25.6g that obtains can be used as diabetics or the hyperglycemia sub-health population is alleviated and the health product of prevent diabetes.
Step 3: the crude polysaccharides that step 2 is obtained passes through Sephadex G-200 column chromatography, and eluent is 0.15M NaCl, and eluent detects through the sulphuric acid phynol method, gets male portion and divides merging, concentrates after the dialysis, and lyophilization gets sample B 6.9g.This sample detects through HPLC, and the result is single symmetrical peak, proves that this polysaccharide is pure product, and these pure product can be used as the treatment medicine of diabetics.
The effect experiment of relevant its hypoglycemic activity:
1. to the hypoglycemic activity of normal mouse and the influence of body weight
10 every group of kunming mices, dosage A is 50mg/kg, B is 25mg/kg; The continuous irrigation stomach is measured its fasting glucose after 7 days.7 days physiology saline of matched group continuous irrigation stomach.
Hypoglycemic activity:
Crude product A compares with matched group the influence such as the table 1. of normal mouse fasting glucose with pure product B, and crude product A and pure product B have obvious hypoglycemic activity (being respectively p＜0.05), and B compares hypoglycemic activity significant difference p＜0.05. with A
Table 1 crude product A and pure product B are to the influence of normal mouse fasting glucose and body weight
| Blood glucose (mmol/L) | Hypoglycemic effect | |
| The blank group | 4.94±0.21 | |
| Crude product A | 4.17±0.12 | 15.6％ |
| Pure product B | 3.92±0.13 | 20.6％ |
The variation of body weight:
By table 2 as seen, compare with matched group, crude product A and pure product B are little to the variable effect of mice body weight, and explanation has no side effect.
Table 2 crude product A and pure product B are to the influence of normal mouse body weight
| Body weight (g/ only) | Growth tendency | ||
| First day | The 7th day | ||
| The blank group | 20.4±1.8 | 24.6±2.3 | 20.6％ |
| Crude product A | 19.8±1.1 | 24.1±1.9 | 21.7％ |
| Pure product B | 20.1±1.5 | 23.9±1.7 | 18.9％ |
2. the hypoglycemic activity of the hyperglycemic rat that alloxan is caused
After Wistar rat alloxan causes hyperglycemia, 10 every group of screening hyperglycemic rats,, the continuous irrigation stomach is measured its fasting glucose after 7 days.Irritating stomach dosage A is 50mg/kg, and B is 25mg/kg.
7 days physiology saline of blank group (10) continuous irrigation stomach; The hyperglycemia matched group is that alloxan causes 7 days physiology saline of continuous irrigation stomach after the hyperglycemia; Hyperglycemia+crude product A group causes 7 days crude product A of continuous irrigation stomach after the hyperglycemia for alloxan; Hyperglycemia+crude product B group causes 7 days pure product of continuous irrigation stomach after the hyperglycemia for alloxan.
Hypoglycemic activity:
As can be seen from Table 3, compare with the hyperglycemia matched group, crude product A and pure product B cause hyperglycemic rat to alloxan and have obvious hypoglycemic activity (being respectively p＜0.05, p＜0.01).
The influence of the hyperglycemic rat fasting glucose that table 3 crude product A and pure product B cause alloxan
| Blood glucose (mmol/L) | Hypoglycemic effect | ||
| First day empty stomach blood glucose value | The 7th day empty stomach blood glucose value | ||
| The blank group | 7.32±0.66 | 7.26±0.75 | No significant change |
| The hyperglycemia matched group | 18.96±1.84 | 18.78±2.23 | No significant change |
| Hyperglycemia+crude product A | 19.21±2.35 | 17.89±1.17 | 6.9％ |
| Hyperglycemia+pure product B | 19.53±1.52 | 14.48±1.09 | 25.9％ |
Influence to body weight:
As can be seen from Table 4, the matched group weight increase, hyperglycemia group body weight obviously reduces, and reduction rate is 7.0%; And the diabetes rat body weight of irritating stomach crude product A and pure product B slightly alleviates, and reduction rate is respectively 2.0% and 1.5%, illustrates that it has certain inhibitory action to alleviating of hyperglycemic rat body weight.
The influence of the hyperglycemic rat body weight that table 4 crude product A and pure product B cause alloxan
| Body weight (g/ only) | Growth tendency | ||
| First day | The 7th day | ||
| The blank group | 201±16.3 | 220±23.4 | 9.5％ |
| The hyperglycemia matched group | 199±9.8 | 185±16.2 | -7.0％ |
| Hyperglycemia+crude product A | 198±13.1 | 194±20.5 | -2.0％ |
| Hyperglycemia+pure product B | 205±14.4 | 202±20.7 | -1.5％ |
3 toxicity tests
After 7 days, none dead mouse is not seen any toxic and side effects and unusual, illustrates that crude product A and pure product B have no side effect with ten times of (A is 500mg/kg, and B is 250mg/kg) continuous irrigation stomach kunming mices of normal dose.
Results such as HPLC, gas chromatogram, infrared spectrum and nuclear magnetic resonance, NMR show that this polysaccharide molecular weight is 270kD, its monosaccharide component is: rhamnose, arabinose, xylose, mannose, galactose, glucose, galacturonic acid, its mol ratio is: 2.2: 2.7: 0.9: 0.6: 4: 2: 2.5, and white powder.
Claims (2)
1, the application of wintercherry fruit polysaccharide in preparation treatment diabetes medicament.
2, wintercherry fruit polysaccharide is in the application of preparation as the health product of alleviation or prevent diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101191454A CN100400048C (en) | 2005-12-28 | 2005-12-28 | Application of physalis alkekengi polysaccharide in preparation of medicine and health care product for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101191454A CN100400048C (en) | 2005-12-28 | 2005-12-28 | Application of physalis alkekengi polysaccharide in preparation of medicine and health care product for treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1823811A true CN1823811A (en) | 2006-08-30 |
| CN100400048C CN100400048C (en) | 2008-07-09 |
Family
ID=36934751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101191454A Expired - Fee Related CN100400048C (en) | 2005-12-28 | 2005-12-28 | Application of physalis alkekengi polysaccharide in preparation of medicine and health care product for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100400048C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474291B (en) * | 2009-01-22 | 2011-08-31 | 东北师范大学 | Application of franchet groundcherry calyx or fruit saponin in preparing medicament and health product for treating diabetes |
| CN107266602A (en) * | 2017-07-27 | 2017-10-20 | 李欣瑜 | Extraction of Polysaccharides in Fruit of Physalis and preparation method thereof |
-
2005
- 2005-12-28 CN CNB2005101191454A patent/CN100400048C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474291B (en) * | 2009-01-22 | 2011-08-31 | 东北师范大学 | Application of franchet groundcherry calyx or fruit saponin in preparing medicament and health product for treating diabetes |
| CN107266602A (en) * | 2017-07-27 | 2017-10-20 | 李欣瑜 | Extraction of Polysaccharides in Fruit of Physalis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100400048C (en) | 2008-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Synthesis, stability and anti-fatigue activity of selenium nanoparticles stabilized by Lycium barbarum polysaccharides | |
| CN101560267B (en) | Preparation method of polysaccharide selenite | |
| KR20050109269A (en) | A ginseng preparation using vinegar and process for thereof | |
| CN1965885A (en) | Application of total flavones of chickpea in preparation of medicament for treating diabetes | |
| CN104997883A (en) | Inonotus obliquus raspberry tree red raspberry composition, inonotus obliquus raspberry tree red raspberry composite oral solution and preparation method and application thereof | |
| CN101190280B (en) | Use of extract of non-fruit part of prune tree | |
| CN1434053A (en) | Rhizoma anemarrhenae extract and preparation process and use thereof | |
| CN101185671A (en) | Anti-tumor medicine extracted from Juglans regia and preparation method thereof | |
| CN1931874B (en) | Preparation process, medicine preparation and medicinal use of ginseng glycopeptide | |
| CN100400048C (en) | Application of physalis alkekengi polysaccharide in preparation of medicine and health care product for treating diabetes | |
| CN101933965A (en) | Mugwort extract and preparation process thereof, and application in controlling postmeal gucose | |
| CN110218262B (en) | Application of low-sulfated heteroglycan rich in glucuronic acid and derived from brown algae in preparation of medicines for treating type 2 diabetes | |
| KR101416671B1 (en) | Ginseng prosapogenin high concentration containing ginseng leaf or stem preparation using sonication and process for thereof | |
| CN101066285A (en) | Application of aweto prepn in preparing medicine for treating skin diseases | |
| CN101278974A (en) | Cinnamon saponins extract, preparation method and application thereof | |
| CN105192820A (en) | Blood-fat-reducing cordyceps militaris polysaccharide beverage and preparing method thereof | |
| CN1865289A (en) | Preparation and uses of polysaccharide from urtica fissa | |
| CN101972284B (en) | Preparation method of pine needle fat soluble extract and application thereof in preparing drug for treating gastric ulcer | |
| JP2021512997A (en) | Separated windproof polysaccharides and their uses | |
| CN112979839A (en) | Preparation method of passion flower leaf acidic polysaccharide | |
| CN107412393B (en) | Preparation method and application of clausena lansium leaf polyphenol extract | |
| CN1290525C (en) | A blood lowering botanical extract and its preparation and preparing process | |
| CN101474291B (en) | Application of franchet groundcherry calyx or fruit saponin in preparing medicament and health product for treating diabetes | |
| CN1171896C (en) | Syringic general saponin extractive and its prepn and medicinal composition | |
| CN1628754A (en) | Local externally applied itch stopping garlic paint |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080709 Termination date: 20100128 |